Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518785 | 0.88 | PDE10A (0.77) | PDE10AALDH1A1 | |
| SCHEMBL3416120 | 0.86 | PDE10A (0.72) | PDE10AALDH1A1 | |
| Balipodect SCHEMBL30123098 | 0.86 | PDE10A (0.77) | PDE10A | |
| SCHEMBL519788 | 0.86 | PDE10A (0.75) | PDE10A | |
| Balipodect SCHEMBL518714 | 0.86 | PDE10A (0.77) | PDE10A | |
| SCHEMBL14729554 | 0.86 | PDE10A (0.68) | PDE10AALDH1A1 | |
| SCHEMBL519123 | 0.86 | PDE10A (1.00) | PDE10AALDH1A1 | |
| SCHEMBL519138 | 0.85 | PDE10A (0.70) | PDE10AALDH1A1 | |
| SCHEMBL518545 | 0.85 | PDE10A (0.70) | PDE10AALDH1A1 | |
| SCHEMBL14723184 | 0.85 | PDE10A (0.70) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2602254-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2602254-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018059-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | PDE5A, PDE3A, PDE3B | PDE10A 6/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.